IGM Biosciences, Inc. Pre-Tax Income
IGM Biosciences, Inc. reported Pre-Tax Income of -$195.79 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Income Statement
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2025-03-06
- IGM Biosciences, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2024-12-31 was -$36.65M.
- IGM Biosciences, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2024-09-30 was -$61.43M.
- IGM Biosciences, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2024-06-30 was -$47.90M.
- IGM Biosciences, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2024-03-31 was -$49.82M.
- IGM Biosciences, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$195.79M.
- IGM Biosciences, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$245.74M.
- IGM Biosciences, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$221.10M.
- IGM Biosciences, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2021 was -$165.16M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$36.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$98.08M derived: sum of 2 quarters · filed 2025-03-06 | -$145.98M derived: sum of 3 quarters · filed 2025-03-06 | -$195.79M 10-K · filed 2025-03-06 |
| 2024-09-30 | -$61.43M 10-Q · filed 2024-11-08 | -$109.33M derived: sum of 2 quarters · filed 2024-11-08 | -$159.15M 10-Q · filed 2024-11-08 | -$219.60M derived: sum of 4 quarters · filed 2025-03-06 |
| 2024-06-30 | -$47.90M 10-Q · filed 2024-08-14 | -$97.72M 10-Q · filed 2024-08-14 | -$158.17M derived: sum of 3 quarters · filed 2025-03-06 | -$219.92M derived: sum of 4 quarters · filed 2025-03-06 |
| 2024-03-31 | -$49.82M 10-Q · filed 2024-05-08 | -$110.27M derived: sum of 2 quarters · filed 2025-03-06 | -$172.02M derived: sum of 3 quarters · filed 2025-03-06 | -$236.33M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-12-31 | -$60.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$122.20M derived: sum of 2 quarters · filed 2025-03-06 | -$186.52M derived: sum of 3 quarters · filed 2025-03-06 | -$245.74M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$61.75M 10-Q · filed 2024-11-08 | -$126.06M derived: sum of 2 quarters · filed 2024-11-08 | -$185.28M 10-Q · filed 2024-11-08 | -$237.86M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | -$64.31M 10-Q · filed 2024-08-14 | -$123.54M 10-Q · filed 2024-08-14 | -$176.11M derived: sum of 3 quarters · filed 2025-03-06 | -$234.15M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | -$59.22M 10-Q · filed 2024-05-08 | -$111.80M derived: sum of 2 quarters · filed 2025-03-06 | -$169.84M derived: sum of 3 quarters · filed 2025-03-06 | -$228.43M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | -$52.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$110.61M derived: sum of 2 quarters · filed 2025-03-06 | -$169.21M derived: sum of 3 quarters · filed 2025-03-06 | -$221.10M 10-K · filed 2025-03-06 |
| 2022-09-30 | -$58.04M 10-Q · filed 2023-11-13 | -$116.63M derived: sum of 2 quarters · filed 2023-11-13 | -$168.53M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | -$58.59M 10-Q · filed 2023-08-03 | -$110.49M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | -$51.89M 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | -$165.16M 10-K · filed 2024-03-07 |